Phio Pharmaceuticals
PHIO
6 hedge funds and large institutions have $98.3K invested in Phio Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, reducing their positions, and 7 closing their positions.
3.63% more ownership
Funds ownership: 6.89% → 10.51% (+3.6%)
11% less capital inflows, than outflows
Capital inflows: $98.9K | Capital outflows: $111K
45% less funds holding
Funds holding: 11 → 6 (-5)
71% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$90.1K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$5.07K |
| 3 |
Tower Research Capital (TRC)
New York
|
+$1.92K |
| 4 |
Nordwand Advisors
Radnor,
Pennsylvania
|
+$1.79K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$11 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
-$24.5K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$19.7K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$16.9K |
| 4 |
Bridgeway Capital Management
Houston,
Texas
|
-$16.4K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$15.2K |
PHIO Hedge Fund Activity: Q3 2024 in Review
6 of the 6,985 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q3 2024, worth a combined $98.3K — down 16% from $117K a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of PHIO and 2 opened new positions — a net loss of 5 holders — while 0 trimmed existing stakes and 3 added.
The largest buyer was Sabby Management, opening a new position worth an estimated $90.1K. The largest seller was Cetera Investment Advisers, exiting entirely with an estimated $24.5K sold.
- 6 institutional investors held Phio Pharmaceuticals (PHIO) as of Q3 2024, down from 11 in Q2 2024.
- Funds reported $98.3K of Phio Pharmaceuticals stock for Q3 2024, down 16% quarter-over-quarter.
- 2 funds opened new Phio Pharmaceuticals positions in Q3 2024 and 7 closed out, a net change of -5 holders.
- The largest Phio Pharmaceuticals buyer in Q3 2024 was Sabby Management, an estimated $90.1K added.
- The largest Phio Pharmaceuticals seller in Q3 2024 was Cetera Investment Advisers, an estimated $24.5K sold.
Based on aggregated 13F filings for Q3 2024.